Article info

Download PDFPDF
The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab

Authors

  1. Address correspondence and reprint requests to Mogens K. Boisen, MD, PhD, Department of Oncology, Herlev University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark. E-mail: Mogens.Karsboel.Boisen{at}regionh.dk.

Citation

Boisen MK, Madsen CV, Dehlendorff C, et al
The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab

Publication history

  • Received October 29, 2015
  • Accepted June 5, 2016
  • First published October 1, 2016.
Online issue publication 
October 01, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.